{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Survival < 1 year post-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Survival 1 to < 5 years post-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Survival 5 to < 10 years post-transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Survival 10+ years post-transplant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Mortality rates in subjects after successful completion of a bone marrow transplant","groups":[{"description":"Chemo, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate\n\nStem Cell Transplant: Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be \\> 5 x 106 CD34+cells/kg of recipient.\n\nPatient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.\n\nDonor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml.\n\nG-CSF: 10 mcg/k","id":"OG000","title":"Study Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 15 Years Post-Transplant","title":"Overall Survival Measured in Participants","type":"SECONDARY","unitOfMeasure":"Participants"}